Service(s) concerned
Structure(s) concerned
Research
1st patient recruited in an onco-hematology clinical trial
First patient recruited at Caen Normandy University Hospital in a study of a new anti-tumor treatment for a rare and aggressive type of cancer called peripheral T-cell lymphoma (PTCL), which affects immune cells.
Antibody treatment brings hope
Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin lymphomas for which the medical need is very great. PTCL are aggressive hematological tumors with a guarded prognosis. Patients are generally treated as first-line chemotherapy, which unfortunately has limited effectiveness, like other treatments whose response rate generally does not exceed 30%.
The antibody developed by XENOTHERA , a Nantes biotech company specializing in the development of innovative treatments, recognizes most PTCLs. It is more effective than chemotherapy on T lymphoma cells, and it has a significant anti-tumor effect, with up to 90% reduction in tumor size in preclinical in vivo models.
The European Medicines Agency (EMA) issued authorization for this Phase I/II trial in April 2024, thus confirming its interest in this innovative treatment in a serious pathology.
The first centers participating in the trial are the Caen Normandy, Bordeaux , Clermont-Ferrand , the AP-HP and the Hospices Civils de Lyon . The first patient was recruited at Caen Normandy University Hospital, more precisely within the Clinical Research Center , by the teams of Professor Gandhi Damaj , international coordinator of this study.
We thank this first patient and Professor Damaj's teams for their involvement and hope that the expected benefits will be confirmed!
Published on September 24, 2024
Share the news
Latest news
Press contacts
Avenue de la Côte de Nacre
CS 30001
14033 CAEN cedex 9